Who we help accelerate
Accelerate your research breakgthroughs and novel drug launches.
Accelerate the scale up of your genetic testing & unlock the value in your data.
NGS Assay & Equipment Manufacturers
Bring new tests to market and scale up testing fast.
Non-Profits and Government Agencies
Accelerate your research breakthroughs and unlock the value in your data.
How we can help
Tap into millions of patient records to accelerate precision medicine.
Clinical & Multi-omic Data Access
Harmonize and augment your data to unlock the value within.
Use cutting edge technology to make new discoveries and breakthroughs faster.
Companion Diagnostic Development & Scaling
Develop better diagnostics that scale faster, accelerating novel drug uptake.
NGS Assay Development & Expansion
Bring new tests to market and scale-up fast.
Effectively navigate and grow in the changing regulatory environment.
Clinical Interpretation & Reporting
Secondary & Tertiary analytics tools enabled by expert clinical services.
Our cutting-edge technology suite
Our Trusted Research Environment (TRE) for bioinformatic analysis & pipeline development.
Our award winning reference genome tool.
Our data harmonization and secure sharing platform.
Born from Pierian, our flagship tertiary analysis and reporting platform delivers confident decision support for NGS testing.
Our best in class, IVD-grade variant interpretation knowledge base.
Our in-house expert teams
Supporting health & life science companies to combine and harmonize their data.
Supporting researchers and diagnostic developers to build better workflows.
Supporting researchers to run efficient and effective studies.
Supporting clinical diagnostic labs and diagnostic test developers to navigate the changing regulatory environment.
Supporting diagnostic labs to start and scale-up their NGS testing.
Our company
Publications, whitepapers, webinars, videos, and more.
The latest from the precision medicine experts at Velsera.
Interested in joining the team? Explore careers here.
Visit our legal section for all of the details.
Home | Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants
June 1, 2020
By The Velsera Clinical and Compliance Team
The identification of tumour mutational burden (TMB) as a biomarker of response to programmed cell death…